Table 2. . Prognostic role of baseline characteristics and prostate-specific antigen response: univariate and multivariate analysis for overall survival.
| Univariate | Median PFS (months) | HR (95% CI) | p-value |
|---|---|---|---|
| PSA response >50%: | |||
| − Yes | 17.0 | 0.23 (0.14–0.39) | <0.001 |
| − No | 5.2 | ref. | |
| Gleason score: | |||
| − <8 | 12.3 | 0.71 (0.43–1.20) | 0.199 |
| − ≥8 | 8.2 | ref. | |
| Primary treated: | |||
| − Yes | 11.3 | 0.99 (0.59–1.68) | 0.992 |
| − No | 9.6 | ref. | |
| Previous docetaxel: | |||
| − No | 13.5 | 0.61 (0.38–0.98) | 0.041 |
| − Yes | 7.7 | ref. | |
| Visceral metastasis: | |||
| − No | 11.3 | 0.97 (0.49–1.91) | 0.934 |
| − Yes | 6.2 | ref. | |
| ECOG: | |||
| − 0–1 | 11.3 | 0.27 (0.11–0.69) | 0.006 |
| − ≥2 | 3.9 | ref. | |
| ALP: | |||
| − <ULN | 12.7 | 0.48 (0.28–0.81) | 0.006 |
| − ≥ULN | 6.2 | ref. | |
| Hemoglobin: | |||
| − ≥12 g/dl | 12.3 | 0.89 (0.54–1.45) | 0.631 |
| − <12 g/dl | 9.2 | ref. | |
| Total PSA: | |||
| − <Median | 16.5 | 0.48 (0.29–0.77) | 0.002 |
| − ≥Median | 6.7 | ref. | |
| LDH: | |||
| − <Median | 9.6 | 1.03 (0.64–1.65) | 0.53 |
| − ≥Median | 11.3 | ref. | |
| Multivariate | |||
| PSA response >50%: | 0.24 (0.14–0.41) | <0.001 | |
| − Yes | ref. | ||
| − No | |||
| Previous docetaxel: | |||
| − Yes | ref. | 0.990 | |
| − No | 0.99 (0.59–1.70) | ||
| ECOG: | |||
| − 0–1 | 0.35 (0.13–0.95) | 0.040 | |
| − ≥2 | ref. | ||
| ALP: | |||
| − <ULN | 0.85 (0.44–1.62) | 0.613 | |
| − ≥ULN | ref. | ||
| Total PSA: | |||
| − <Median | 0.62 (0.35–1.09) | 0.099 | |
| − ≥Median | ref. |
ECOG: Eastern Cooperative Oncology Group; HR: Hazard ratio; IQR: Interquartile range; OS: Overall survival; PFS: Progression-free survival; PSA: Prostate-specific antigen; ULN: Upper limit of normal.